Brief: Enlivex Announces Q2 Results
09/08/2021 14:29
Aug 9 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX THERAPEUTICS LTD - BELIEVES EXISTING CASH,
SECURITIES
WILL BE SUFFICIENT TO FUND EXPENSES AND CAPEX THROUGH 2023
Source text for Eikon: ID:nGNX9H86X7
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment